Verastem (VSTM) Income from Continuing Operations (2011 - 2026)
Verastem (VSTM) posted quarterly Income from Continuing Operations of 44455000.0 for Q1 2026, little changed year-over-year from 44504108.26 in Q1 2025, and down 1487.92% quarter-over-quarter from 3203000.0 in Q4 2025.
Powered by 
Analysis
Verastem (VSTM) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Verastem's Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 44455000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations changed 0.11% year-over-year to 44455000.0; the TTM figure through Mar 2026 stood at 139479000.0 (down 5.54% YoY), while the FY2025 annual figure was 165482000.0, down 26.66% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 44455000.0, down from 3203000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 3203000.0 in Q4 2025, with the low at 53951000.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 21958000.0 (2022), against an average of 27470117.65.
- Peak annual rise in Income from Continuing Operations reached 110.02% in 2025, while the deepest fall reached 192.7% in 2025.
- Verastem's Income from Continuing Operations stood at 16801000.0 in 2022, then slumped by 80.88% to 30390000.0 in 2023, then fell by 5.19% to 31968000.0 in 2024, then surged by 110.02% to 3203000.0 in 2025, then plunged by 1487.92% to 44455000.0 in 2026.
- Business Quant data shows VSTM's Income from Continuing Operations at 44455000.0 in Q1 2026, 3203000.0 in Q4 2025, and 44276000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Verastem | 801.43 Mn | 665.08 Mn | 36.32 Mn | -34.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -34.67 Mn |
| Mar 31, 2026 | -43.98 Mn |
| Dec 31, 2025 | 3.20 Mn |
| Sep 30, 2025 | -39.85 Mn |
| Jun 30, 2025 | -25.93 Mn |
| Mar 31, 2025 | -43.41 Mn |
| Dec 31, 2024 | -31.97 Mn |
| Sep 30, 2024 | -37.35 Mn |
| Jun 30, 2024 | -18.43 Mn |
| Mar 31, 2024 | -27.82 Mn |
| Dec 31, 2023 | -30.39 Mn |
| Sep 30, 2023 | -20.19 Mn |
| Jun 30, 2023 | -20.29 Mn |
| Mar 31, 2023 | -19.14 Mn |
| Dec 31, 2022 | -16.80 Mn |
| Sep 30, 2022 | -18.11 Mn |
| Jun 30, 2022 | -21.96 Mn |
| Mar 31, 2022 | -16.99 Mn |
| Dec 31, 2021 | -16.48 Mn |
| Sep 30, 2021 | -22.79 Mn |